Evidence map›Paper›PMID 28534152›Full record

ArticleJournal of neuro-oncology2017

Cerebrospinal fluid dissemination of high-grade gliomas following boron neutron capture therapy occurs more frequently in the small cell subtype of IDH1

Natsuko Kondo, Rolf F Barth, Shin-Ichi Miyatake, Shinji Kawabata, Minoru Suzuki, Koji Ono, Norman L Lehman

Open access · greenAbstract read
In one paragraph

Article in Journal of neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Natsuko KondoParticle Radiation Oncology Research Center, Kyoto University Research Reactor Institute, Sennan-gun, Osaka, Japan. nkondo@rri.kyoto-u.ac.jp.
Rolf F BarthDepartment of Pathology, The Ohio State University Medical Center, Columbus, OH, USA.
Shin-Ichi MiyatakeDepartment of Neurosurgery, Osaka Medical College, Takatsuki City, Osaka, Japan.
Shinji KawabataDepartment of Neurosurgery, Osaka Medical College, Takatsuki City, Osaka, Japan.
Minoru SuzukiParticle Radiation Oncology Research Center, Kyoto University Research Reactor Institute, Sennan-gun, Osaka, Japan.
Koji OnoParticle Radiation Oncology Research Center, Kyoto University Research Reactor Institute, Sennan-gun, Osaka, Japan.
Norman L LehmanDepartment of Pathology, The Ohio State University Medical Center, Columbus, OH, USA. nllehman@yahoo.com.
Kyoto University Research Reactor Institute · JPOsaka Medical and Pharmaceutical University · JPThe Ohio State University · USThe Ohio State University Wexner Medical Center · US

Funding

Aurora-A is a novel therapeutic target in glioblastomaR01NS081125 · NINDS · UNIVERSITY OF LOUISVILLE · PI LEHMAN, NORMAN · 2014 to 2019
$1.8M
NINDS NIH HHS R01 NS081125
6 · The paper itself

Abstract

We have used boron neutron capture therapy (BNCT) to treat patients in Japan with newly diagnosed or recurrent high-grade gliomas and have observed a significant increase in median survival time following BNCT. Although cerebrospinal fluid dissemination (CSFD) is not usually seen with the current standard therapy of patients with glioblastoma (GBM), here we report that subarachnoid or intraventricular CSFD was the most frequent cause of death for a cohort of our patients with high-grade gliomas who had been treated with BNCT. The study population consisted of 87 patients with supratentorial high-grade gliomas; 41 had newly diagnosed tumors and 46 had recurrent tumors. Thirty of 87 patients who were treated between January 2002 and July 2013 developed CSFD. Tumor histology before BNCT and immunohistochemical staining for two molecular markers, Ki-67 and IDH1

Indexed as

Boron Neutron Capture TherapyAdolescentAdultAgedBrainBrain NeoplasmsCerebrospinal Fluid LeakFemaleFollow-Up StudiesGenetic Predisposition to DiseaseGliomaHumansIsocitrate DehydrogenaseMaleMiddle AgedNeoplasm GradingIDH1 protein, humanIsocitrate DehydrogenaseAnaplastic oligodendrogliomaBoron neutron capture therapyCerebrospinal fluid disseminationHigh-grade gliomaSmall cell glioblastoma

Identifiers

PMID28534152
PMCPMC5786264
OpenAlexW2616958536

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.